Danaher (DHR) Q2 2026 Earnings Call Transcript
Danaher (DHR) reported Q2 2026 revenue of $6.3B, up 3% in core terms, with non-respiratory core growth accelerating to 4.5%. Adjusted diluted EPS rose 8% to $1.94 and free cash flow was $1.3B. The company raised full-year EPS guidance to $8.45-$8.60 and core revenue to 3%-4%, citing early Masimo acquisition close and timing delays shifting about $100M of chromatography resin revenue into 2027.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year EPS range, Q3 revenue and margin guidance, and disclosed revenue timing delays that shift roughly $100M from 2026 into 2027.
Market read
Guidance and segment execution details provide a clear catalyst for repricing Danaher’s earnings expectations, with specific offsets from respiratory testing and shipment timing.
What to watch
Respiratory testing creates a stated 250 bps YoY headwind in Q3, and consumables growth was below expectations due to large shipments moving out of the quarter.
Background
This is Danaher’s Q2 2026 earnings call transcript, covering segment performance, acquisition updates (Masimo closed, StatLab pending), and updated guidance.
Ticker impact
Danaher reported Q2 results and raised full-year EPS guidance to $8.45 to $8.60, citing early Masimo acquisition close and improved life sciences performance.
Likely near-term positive bias as guidance is raised, partially offset by disclosed timing delays and respiratory testing headwinds for Q3.
The article provides multiple concrete forward-looking datapoints (raised FY EPS range, Q3 revenue and margin guidance, and specific revenue timing shift) that directly affect Danaher’s earnings trajectory and segment mix.
Market effects
Signals continued demand normalization in life sciences and diagnostics, with bioprocessing equipment/orders growing despite chromatography resin shipment timing.
China biotechnology growth continued, with volume-based procurement impacts moderating.
FDA 510(k) clearance for Masimo’s AI-enabled detection solution reinforces regulatory progress for medtech diagnostics tools.
Counterpoint
The guidance raise may be partially offset by revenue timing shifts (chromatography resin) and consumables shipment delays, which could pressure near-term execution versus the headline EPS uplift.
Key entities
- public_companyDanaher Corporation
Reported Q2 2026 results and raised FY EPS guidance; discussed segment trends and acquisition-related contributions.
- acquired_companyMasimo
Acquisition closed in early June 2026; received FDA 510(k) clearance for an AI-enabled opioid-induced respiratory depression detection solution.
- pending_acquisition_targetStatLab
Pathology consumables acquisition pending; described as accretive to adjusted EPS in the first full year and >85% recurring revenue.
